Clinical Characteristics, Diagnosis and Management of Nivolumab-induced Myocarditis: Hypersensitivity Myocarditis, or Something else
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Li M, He Y, Huang S, Hu X, Chen J
. Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis. Invest New Drugs. 2024; 42(1):116-126.
DOI: 10.1007/s10637-024-01421-7.
View
2.
Bharathidasan K, Abdelnabi M, Abdelmalek J, Sekhon J, Butler W, Quirch M
. Nivolumab-induced fatal myocarditis: A case report. Clin Case Rep. 2023; 11(5):e7306.
PMC: 10167613.
DOI: 10.1002/ccr3.7306.
View
3.
Banini M, Salvestrini V, Vultaggio A, Perlato M, Mecheri V, Cerbai C
. Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review. Curr Oncol. 2023; 30(7):6699-6707.
PMC: 10378378.
DOI: 10.3390/curroncol30070491.
View
4.
Sobol I, Chen C, Mahmood S, Borczuk A
. Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy. Arch Pathol Lab Med. 2020; 144(11):1392-1396.
PMC: 8445131.
DOI: 10.5858/arpa.2019-0447-OA.
View
5.
Kounis N, Zavras G, Soufras G, Kitrou M
. Hypersensitivity myocarditis. Ann Allergy. 1989; 62(2):71-4.
View